Search
tRNA-dihydrouridine(20) synthase [NAD(P)+]-like
go.drugbank.com/bio_entities/BE0020091EnzymeHumansCatalyzes the NADPH-dependent synthesis of dihydrouridine, a modified base found in the D-loop of most tRNAs (PubMed:15994936, PubMed:26429968, PubMed:30149704, PubMed:34798057, PubMed:38680565). Specifically modifies U20 in cytoplasmic ...
Polypeptides: tRNA-dihydrouridine(20) synthase [NAD(P)+]-likeYellow fever vaccine
go.drugbank.com/drugs/DB10805ApprovedInvestigational; in two separate clinical trials of Yellow Fever Vaccine, 90% of subjects seroconverted within 10 days after vaccination, and 100% of subjects seroconverted within 14 days [FDA Label]. … The World Health Organization no longer recommends the use of a 10-year booster dose following primary immunization, as a single dose is "sufficient to confer life-long immunity against yellow fever disease
Synonyms: Flavivirus yellow fever virus 17D-204 whole, Yellow fever virus strain 17D-204 live antigenProducts: STAMARIL 0,5 ML IM/SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN FLAKON VE ÇÖZÜCÜ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 10 ADET, STAMARIL 0,5 ML IM/SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN FLAKON VE ÇÖZÜCÜ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETIdarucizumab
go.drugbank.com/drugs/DB09264ApprovedIdarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its … Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations.
Products: PRAXBİND 50 MG/ML ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİ, 2 ADET, PRAXBIND Solution for Injection/Infusion 50 mg/mlEtofenamate
go.drugbank.com/drugs/DB08984InvestigationalEtofenamate is used to treat muscle and joint paint. It is a non-steroidal anti-inflammatory drug (NSAID).
Mixtures: HOTFİX 100 MG/G + 10 MG/G KREM , 50 GRAM, THERMO RHEUMON 100 MG/G + 10 MG/G KREM, 50 GCategories: Non COX-2 selective NSAIDSRavulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigational[A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults. … [A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis.
Products: Ultomiris 300 mg/3 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (1 adet), ULTOMIRIS ® RAVULIZUMAB 100MG/ML.Levomethadone
go.drugbank.com/drugs/DB13515InvestigationalCategories: Drugs Used in Opioid Dependence, Drugs Used in Addictive DisordersProducts: Levo-Methasan 10 mg-Tabletten, L-Polamidon 20 mg TablettenBenralizumab
go.drugbank.com/drugs/DB12023ApprovedInvestigational[A31293] Benralizumab was FDA approved on November 14, 2017, and was developed by MedImmune, AstraZeneca's global biologic research and development arm.[L1019] … It is an afucosylated IgG which gives it high affinity for the FcγRIIIα receptor in natural killer cells, macrophages and neutrophils.
Products: Fasenra 30 mg solution for injection in pre-filled syringe, FASENRA 30 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖRCycloserine
go.drugbank.com/drugs/DB00260ApprovedInvestigationalAntibiotic substance produced by Streptomyces garyphalus.
Categories: Heterocyclic Compounds, 1-RingProducts: SIKLOCAP 250 MG KAPSUL, 40 ADET, SIKLOCAP 250 MG KAPSUL, 500 ADETPicosulfuric acid
go.drugbank.com/drugs/DB09268ApprovedInvestigationalThe combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.[A33322] … Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery.
Mixtures: PICOPREP 10 MG / 3,5 G /12 G ORAL ÇÖZELTI IÇIN TOZ, 2 SAŞE, CITRAFLEET 0.01 G/ 3.50 G/ 10.97 G ORAL ÇÖZELTI HAZIRLAMAK IÇIN TOZ IÇEREN SAŞE , 2 ADETCategories: Heterocyclic Compounds, 1-RingElranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigational[L47815] On August 14, 2023, the FDA granted accelerated approval to elranatamab for the treatment of multiple myeloma. … It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one
Synonyms: -CHAIN) (HUMAN-MUS MUSCULUS MONOCLONAL PF-06863059 .GAMMA.2-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL PF-06863059 .KAPPA.-CHAIN, (223->217')(2Products: Elrexfio 44 mg/1,1 ml Enjeksiyonluk Çözelti, 1 ADET, Elrexfio 76 mg/1,9 ml Enjeksiyonluk Çözelti, 1 ADET